The screening was, however, designed in a way that only MMR deficient tumors were referred to MSI testing and/or genetic analyses, which results in the lack of identification of Lynch syndrome tumors that are MMR proficient but MSI. The gene discussed is MRC1; the disease is Lynch syndrome.